Cigna Group (NYSE:CI) reaffirmed its 2026 outlook and outlined a long-term strategy centered on complex care, technology-enabled personalization and disciplined capital deployment at its 2026 Investor Day.
President and CEO Brian Evanko said the company has reshaped its portfolio over the past decade from a predominantly employer-focused health plan into three growth platforms: Evernorth Specialty and Care Services, Evernorth Pharmacy Benefit Services and Cigna Healthcare. He said the company has reduced exposure to businesses where it lacked a competitive advantage, including its Medicare operations, while expanding specialty pharmacy and complex-care capabilities.
Focus on complex care and personalization
Evanko introduced the company’s “Lead to One” strategy, which aims to deliver personalized healthcare support at scale. The approach is intended to serve members across the health continuum, from preventive care to individuals with chronic and complex conditions.
According to Evanko, 8% of patients have complex care needs but account for 55% of healthcare spending. Cigna said all spending within its Specialty and Care Services business is tied to complex conditions, while approximately 55% of spending it manages in Cigna Healthcare and 70% of spending in Pharmacy Benefit Services is associated with complex care.
The company said its Health Intelligence Engine combines medical, pharmacy, behavioral-health and other data with clinical expertise, analytics and artificial intelligence to identify risks and guide personalized actions. Chief Data, Digital and AI Officer Katya Andresen said current AI applications have reduced phone calls per customer by 20% over the past several years, reduced clinical documentation time at MDLIVE by up to 90%, and shortened a specialty benefit-review process from 15 minutes to 21 seconds.
Cigna also highlighted a partnership with Sierra AI for conversational and agentic AI capabilities, as well as a recently announced collaboration with OpenAI focused on clinical AI. Chief Medical Officer Dr. Amy Flaster said the OpenAI work initially will focus on oncology through tools embedded in Accredo and Cigna Healthcare offerings. She emphasized that AI will augment rather than replace clinicians’ judgment.
Specialty services expected to drive growth
Matt Perlberg, president of Evernorth Pharmacy and Care Delivery, said specialty drugs represent a roughly $480 billion market growing at a high-single-digit rate. He said Evernorth’s specialty ecosystem serves more than 1 million patients and generates more than $100 billion in annual revenue.
Accredo, the company’s specialty pharmacy, produces approximately $80 billion in annual revenue and handles more than 8 million specialty prescriptions annually, Perlberg said. About 40% of Accredo revenue comes from sources outside Cigna and Express Scripts, he added. The company cited access to more than 330 limited-distribution drugs, including more than 30 products exclusively available through Accredo.
CuraScript, Evernorth’s specialty-distribution business, generates about $25 billion in annual revenue and has grown roughly 20% annually over the past five years, Perlberg said. Cigna expects Specialty and Care Services to deliver 8% to 12% annual earnings growth through 2030, represent more than 40% of company earnings by that year and add about $20 billion in new distribution revenue.
PBM model shifts toward fee-based structure
Adam Kautzner, president of Evernorth Care Management and Express Scripts, said Pharmacy Benefit Services manages $140 billion annually, serves 117 million Americans and expects to process more than 2 billion prescriptions in 2026.
The business is transitioning to Evernorth Signature, a rebate-free, fee-based pharmacy-benefit model that Cigna said is designed to provide upfront patient discounts, greater client transparency and a flat administrative fee not tied to drug costs. The company plans to launch Signature for Cigna Healthcare’s fully insured business in 2027, with commercial clients able to enroll beginning in 2028.
Cigna expects at least 50% of eligible members to be enrolled in Signature models by the end of 2028. Kautzner said the company expects Pharmacy Benefit Services earnings growth of flat to 4% annually through 2030 as it manages a changing rebate environment and shifts toward a more predictable fee-based model.
Efficiency initiative and capital plans
Dennison announced a $3 billion multiyear modernization and productivity initiative spanning 2026 through 2030. The effort will focus on workflow automation, workforce optimization and supplier, partner and vendor efficiency. She characterized the program as a savings initiative, with some savings reinvested in the business and some contributing to earnings.
The company expects approximately $50 billion in cash flow from operations over the 2026-2030 period. Dennison said Cigna intends to prioritize business investment, maintain a dividend payout ratio of about 20%, continue share repurchases and pursue bolt-on acquisitions that are strategically aligned and financially accretive. The company said it has more than $6 billion remaining under its share-repurchase authorization.
About Cigna Group (NYSE:CI)
The Cigna Group (NYSE: CI) is a global health company that provides health care and related services to individuals, employers, government organizations and health plans. Its operations are primarily organized through Cigna Healthcare and Evernorth Health Services, which together address health coverage, pharmacy services, care delivery and benefit management.
Cigna Healthcare offers medical, dental, behavioral health, disability and other benefits, with a focus on employer-sponsored and individual health plans in the United States as well as international health services.
